A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis
Version of Record online: 9 DEC 2005
Copyright © 1994 American College of Rheumatology
Arthritis & Rheumatism
Volume 37, Issue 5, pages 637–643, May 1994
How to Cite
Landewé, R. B. M., Goeithè, H. S., Van Rijthoven, A. W. A. M., Breedveld, F. C. and Dijkmans, B. A. C. (1994), A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis & Rheumatism, 37: 637–643. doi: 10.1002/art.1780370506
- Issue online: 9 DEC 2005
- Version of Record online: 9 DEC 2005
- Manuscript Accepted: 5 OCT 1993
- Manuscript Received: 18 JUN 1993
Objective. To investigate whether low-dose cyclosporin A (CSA) is safe and effective in comparison with chloroquine (CQ) in patients with early rheumatoid arthritis (RA).
Methods. We performed a randomized, double-blind study comparing CSA with CQ in patients with early RA (duration <2 years) who had had active disease for at least 3 months. Forty-four RA patients with a mean disease duration of 6 months were randomly allocated to receive CSA (initial dosage 2.5 mg/kg/day, maintenance dosage 3.6 mg/kg/day) or CQ (initial dosage 300 mg/day, maintenance dosage 100 mg/day) for 24 weeks.
Results. Five patients (2 taking CSA and 3 taking CQ) discontinued the study prematurely. Intention-to-treat analysis disclosed a decrease in the swollen joint count by 7 in both groups. The erythrocyte sedimentation rate and C-reactive protein level did not change significantly. CSA and CQ were tolerated equally well, although mild paraesthesia occurred more frequently in the CSA-treated group. The serum creatinine level increased by 13 μmoles/liter (95% confidence interval [95% CI] 4, 22) in the CSA group and by 6 μmoles/liter (95% CI 1, 11) in the CQ group (difference not statistically significant).
Conclusion. Both CSA and CQ are effective in alleviating the symptoms of active early RA. There is only slightly impaired renal function after 24 weeks of drug administration of either drug in patients with early RA.